SLC25A1 and steatosis: These results argue that the activity of Slc25a1 is dose-dependent and rate-limiting in the adipose tissue under conditions of metabolic overload imposed by the HFD,—given that a reduction of dosage herein was sufficient to blunt body weight gain—but not in the liver, where only mice with nearly complete loss of Slc25a1 protein were resistant to steatosis.